Guardant Health, Inc. — Blitz Index 42 (C)
Guardant Health scores 42 — nine-month revenue up 42.4% with Shield screening up 180%, held back by negative equity of $275.9 million, $1,493.2 million of convertible debt, a willful-infringement verdict, and two False Claims Act investigations — and the deductions land exactly on the FLAG line.
Last re-scored: November 7, 2026.
Confidence: Medium · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 17 / 25 | Nine-month revenue +42.4% YoY and Q3 +36.1%, with growth accelerating every year since FY2023 — but capital is raised, not generated: nine-month operating cash outflow of $147.1M and a $490.7M maturity due in 2027 |
| B · Moat | 29 / 60 | A data flywheel and reimbursement-led distribution — Shield coverage above 80% of the eligible population — but no platform lock-in, and a 65% gross margin that operating losses still consume |
| C · Creative destruction | 11 / 15 | Blood-based liquid biopsy displacing invasive tissue biopsy and colonoscopy — the first FDA-approved comprehensive liquid-biopsy companion diagnostic and the first blood-based colorectal screening test |
| D · BlitzFailing | −15 | Negative equity of $275.9M plus $1,493.2M of convertibles, two False Claims Act investigations, a 28% single customer, and a willful-infringement verdict with a $0–$270M loss range — exactly on the FLAG line |
Think we scored it wrong? Score it yourself →
Radar axes (0–100): Moat 48.3 · Speed 68.0 · Creative 73.3.
Watch item
Gates: G1 ✓ (confirmed — growth accelerating to +42.4% in nine months of 2026 plus Shield as a second growth curve) · G2 ✓ (estimated — all four vendor estimates of the 2036 liquid-biopsy market clear the $12.79B bar, though the narrowest definition clears it by only 8%). 23 points below the 65-point threshold — the growth is accelerating, but it is funded by debt, and the deductions sit exactly on the FLAG line. Watch the TwinStrand appeal and the False Claims Act investigation outcomes, the $490.7M maturity due in 2027, and whether Shield guidance of $233M–$238M for FY2026 is achieved.
Strengths
- Accelerating growth: nine-month revenue $997.6M (+42.4% YoY), Q3 $361.0M (+36.1%), FY2026 guidance $1.36B–$1.37B (+38–40%, raised)
- Shield as a second growth curve: screening revenue $5.1M in FY2024 → $79.7M in FY2025 → $162.1M in nine months of 2026, Q3 +180% with test volume +246% YoY
- First-of-kind FDA titles: the first comprehensive liquid-biopsy companion diagnostic (Guardant360 CDx) and the first blood-based colorectal screening test (Shield), which meets Medicare coverage requirements
- Reimbursement-led distribution: Shield commercial coverage above 80% of the eligible population (about 100 million lives), NCCN guideline listing, VA and TRICARE coverage
- High gross margin: 64.5% in FY2025, 65% GAAP and 67% non-GAAP in Q3 2026; capital raising demonstrated with $1,002.5M of convertibles in 2025 and about $472M of equity in 2023
Concerns
- Negative equity: shareholder equity of $(275.9)M, accumulated deficit of $(3,351.1)M, total liabilities of $2,161.5M above total assets of $1,885.6M
- Debt burden: $1,493.2M of convertible principal, net debt of about $347.2M, $490.7M of 2027 notes maturing in 2027, and guided FY2026 free-cash-flow burn of $205–220M
- Deep losses: nine-month operating loss of $(383.2)M, net loss of $(356.6)M, operating cash outflow of $(147.1)M — losses since inception
- TwinStrand willful-infringement verdict: $83.4M accrued, possible loss range of $0–$270M, a 6% ongoing royalty, and $110.2M of restricted cash posted as appeal security
- Two False Claims Act civil investigative demands in progress (2022 and 2026) plus a single customer at 28% of revenue (name undisclosed) and variable-consideration revenue recognition that can reverse if reimbursement estimates change
Research notes
Thesis: accelerating growth, debt-funded
Guardant Health enters the BlitzLab record with a first scoring of 42 out of 100, grade C, built from Speed 17 out of 25, Moat 29 out of 60, Creative Destruction 11 out of 15, and deductions of 15. The total sits 23 points below the 65-point line, and the shape of the score is the story: on the radar conversion used by the model, Creative Destruction converts to 73.3, Speed to 68.0, and Moat to only 48.3. This is a liquid-biopsy company — trailing-twelve-month revenue of $1,278.9 million — whose growth is accelerating every year, whose Shield blood test is opening a second growth curve in cancer screening, and whose balance sheet is in negative equity. Both gates pass, so the scoring proceeds, but the second gate passes only as an estimate, on vendor market estimates that disagree by more than threefold, and the deductions land exactly on the FLAG line — the model flags the company at the precise boundary.
The gates: both pass — and the FLAG sits exactly on the line
Gate 1, sustained growth or a second growth curve for a mature company, passes on a confirmed basis. Revenue grew from $563.9 million in fiscal 2023 to $982.0 million in fiscal 2025, then $997.6 million in the first nine months of 2026, up 42.4% year on year, with the growth rate accelerating at every step — fiscal 2023 +25.5%, fiscal 2024 +31.0%, fiscal 2025 +32.9%, nine months of 2026 +42.4% — and fiscal 2026 guidance raised to $1.36–$1.37 billion. The second growth curve is Shield: screening revenue of $5.1 million in fiscal 2024 became $79.7 million in fiscal 2025 and $162.1 million in nine months of 2026, with third-quarter revenue up 180% and test volume up 246%. Gate 2, a ten-year market ceiling at least ten times current revenue, also passes, but the file declares its market definition before doing the arithmetic and marks the verdict as an estimate. Revenue is total GAAP revenue, since the company's test services have no pass-through fee character that would require a contribution-profit normalization. The bar is about $12.79 billion, ten times trailing-twelve-month revenue of $1,278.9 million. The addressable market is the liquid-biopsy market — blood-based cancer testing for therapy selection, residual-disease monitoring, and screening — and four independent vendor estimates of its 2025 size range from $4.03 billion to $13.6 billion, extrapolating to about $13.8–$45.2 billion by 2036, or 1.08 to 3.5 times the bar. All four clear the bar, so the gate passes, but the narrowest definition clears it by only 8%, which is why the verdict is an estimate rather than confirmed. The FLAG is the other half of the gate story: deductions of 15 points reach the FLAG line exactly — debt of minus 6, revenue quality of minus 5, and regulatory cost of minus 4 — so the company is flagged at the boundary, not beyond it. If the TwinStrand loss range settles at its $270 million top end or a False Claims Act investigation produces a finding, the deductions deepen; if the appeal or the patent challenges succeed, they ease.
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (61/B).
Next earnings
Q4 2026 · Expected
Coverage
Guardant Health, Inc. · Next earnings unconfirmed at scoring · Score 42 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.